Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 13/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096905 | 0.84 | KMT2A (0.41) | — | |
| SCHEMBL12967879 | 0.84 | NPC1 (0.43) | SIGMAR1 | |
| SCHEMBL2384190 | 0.79 | ALDH1A1 (0.47) | NOTUMSIGMAR1 | |
| SCHEMBL2615992 | 0.78 | NOTUM (0.51) | NOTUMABL1SIGMAR1 | |
| SCHEMBL1357584 | 0.78 | NOTUM (0.51) | NOTUMABL1SIGMAR1 | |
| SCHEMBL12789222 | 0.77 | KDM1A (0.41) | NOTUMABL1 | |
| SCHEMBL29000076 | 0.77 | ALDH1A1 (0.46) | NOTUMSIGMAR1 | |
| SCHEMBL30354367 | 0.77 | ALDH1A1 (0.46) | NOTUMSIGMAR1 | |
| SCHEMBL3264830 | 0.76 | POLB (0.55) | NOTUM | |
| SCHEMBL30264085 | 0.76 | POLB (0.55) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116003322-B | Pyrazole ether compound as well as preparation method and application thereof | 南通泰禾化工股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-116003322-A | Pyrazole ether compound as well as preparation method and application thereof | 南通泰禾化工股份有限公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2023284761-A1 | PYRAZOLE ETHER COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南通泰禾化工股份有限公司 | 2023-01-19 | — | — | WO | disclosed |
| WO-2023284761-A1 | PYRAZOLE ETHER COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 南通泰禾化工股份有限公司 | 2023-01-19 | — | — | WO | disclosed |
| CN-105061322-B | The preparation method of the 3- hydroxypyrazoles compounds of N- substitutions | 北京颖泰嘉和生物科技股份有限公司 | 2018-07-24 | — | — | CN | disclosed |
| EP-1996580-B1 | PYRRAZOLE DERIVATIVES AS SIGMA RECEPTORS ANTAGONISTS | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| EP-1996580-B1 | PYRRAZOLE DERIVATIVES AS SIGMA RECEPTORS ANTAGONISTS | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| CN-105061322-A | Preparation method of N-substituted 3-hydroxypyrazole compound | BEIJING NUTRICHEM CO LTD | 2015-11-18 | — | — | CN | disclosed |
| US-8470867-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-25 | — | — | US | disclosed |
| US-8470867-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-25 | — | — | US | disclosed |
| US-20080125416-A1 | Sigma Receptor Inhibitors | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2008-05-29 | — | — | US | disclosed |
| WO-2007098964-A2 | PYRRAZOLE DERIVATIVES AS SIGMA RECEPTORS ANTAGONISTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| WO-2007098964-A2 | PYRRAZOLE DERIVATIVES AS SIGMA RECEPTORS ANTAGONISTS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-09-07 | — | — | WO | disclosed |
| EP-1829873-A1 | Pyrrazole derivatives as sigma receptors antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| EP-1829873-A1 | Pyrrazole derivatives as sigma receptors antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-09-05 | — | — | EP | disclosed |
| EP-1781618-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006021462-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021462-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-02 | — | — | WO | disclosed |
| EP-0946514-B1 | METHOD FOR PRODUCING N-SUBSTITUTED 3-HYDROXYPYRAZOLES | BASF AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| US-6040458-A | Method for producing N-substituted 3-hydroxypyrazoles | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125416-A1 | Sigma Receptor Inhibitors | SIGMAR1, TMEM97, OPRL1 | NOTUM 1466/4885ABL1 1130/4885SIGMAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.